Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms Bullseye; Bullseye-2
- 30 Oct 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 30 Oct 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2025.
- 30 Oct 2024 Status changed from recruiting to active, no longer recruiting.